Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Advances in the Treatment of Acute Myeloid Leukemia with TP53 Mutations-Review].

Zhongguo shi yan xue ye xue za zhi - 1 Apr 2026

Zhou Yan-Han, Ye Pei-Pei

Abstract excerpt

Acute myeloid leukemia (AML) is the most common hematological malignancies in adults. TP53, as a tumor suppressor gene, has a mutation rate of about 5%-10% in AML patients. In 2017, the European Leukemia Net first classified AML with TP53 mutations as an unfavorable risk group, highlighting its importance of its importance in predicting prognosis. Currently, the treatment for TP53-mutated AML mainly includes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to TP53 gene
Share to Hematopoietic Stem Cell Transplantation
Share to Leukemia, Myeloid, Acute

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Prognosis

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 42227463
DOI: 10.19746/j.cnki.issn1009-2137.2026.02.044

Genes

TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Advances in the Treatment of Acute Myeloid Leukemia with TP53 Mutations-Review].PMID 42227463Read ↗

What have we learned about TP53-mutated acute myeloid leukemia?Semantic proximity Read ↗

TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?Semantic proximity Read ↗

Molecular Characterization and Clinical Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Patients With TP53 Mutation.Semantic proximity Read ↗

Current State and Future Prospects of Diagnosis and Management of TP53-Mutated Myeloid Neoplasms.Semantic proximity Read ↗

TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation.Semantic proximity Read ↗

[Biological and clinical significance of TP53 mutations in myelodysplastic syndrome and acute myeloid leukemia].Semantic proximity Read ↗

TP53 -Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk-Stratification, and Management.Semantic proximity Read ↗

Moving toward individualized target-based therapies in acute myeloid leukemia.Semantic proximity Read ↗

TP53 signal pathway confers potential therapy target in acute myeloid leukemia.Semantic proximity Read ↗

TP53 in AML and MDS: The new (old) kid on the block.Semantic proximity Read ↗

Breaking the guardian of the genome: TP53 dysfunction in myeloid neoplasms.Semantic proximity Read ↗

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future Considerations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.